Tv Therapeutics Inc. (NASDAQ:VTVT) is one of the best hot stocks to buy according to analysts. On March 10, vTv Therapeutics ...
Compare two ultra-low-cost ETFs with distinct sector focuses and dividend profiles to see which aligns with your investing ...
As of Friday, March 13, vTv Therapeutics Inc.’s VTVT share price has surged by 7.43%, which has investors questioning if this ...
HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential ...
Tv Therapeutics (VTVT) closed the last trading session at $38.13, gaining 12.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...
vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the most promising micro-cap stocks according to analysts. On February 2, vTv Therapeutics expanded its partnership with Newsoara Biopharma Co. Ltd., ...
(VTVT) on Tuesday reported a loss of $7.1 million in its fourth quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 58 cents. The results beat Wall Street ...
Fintel on MSN
Evercore ISI Group initiates coverage of VTV Therapeutics (VTVT) with outperform recommendation
Fintel reports that on March 12, 2026, Evercore ISI Group initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Outperform recommendation. Analyst Price Forecast Suggests 55.01% Upside As of ...
Received $20.0 million in February 2026 from Newsoara under an amended licensing agreementExpect to complete enrollment in the CATT1 Phase 3 ...
Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance ...
Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.
I think VTVT is a largely underfollowed T1D catalyst story, with Phase 3 CATT1 cadisegliatin topline expected in 2H2026. Cadisegliatin’s Phase 2 SimpliciT-1 showed HbA1c improvement, fewer severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results